Pluristem Therapeutics: The FDA Cleared Phase 2 Study of Its PLX Cells in Treating the Respiratory Complications of COVID-19

Pluristem Therapeutics IND Cleared by FDA for PLX Cells in COVID-19 Treatment

From Pluristem Therapeutics (PSTI) we learned that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for a Phase 2 study of its PLX cells in the treatment of severe COVID-19 cases complicated by Acute Respiratory Distress Syndrome (ARDS).

According to its title, “A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 2 Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX-PAD for the Treatment of severe COVID-19”, the study is designed to treat 140 adult patients that are intubated and mechanically ventilated, are suffering from respiratory failure and ARDS due to COVID-19.

Leave a Reply